These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 10762530)

  • 1. Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS.
    Río J; Montalban X
    Neurology; 2000 Apr; 54(8):1710. PubMed ID: 10762530
    [No Abstract]   [Full Text] [Related]  

  • 2. Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial.
    Río J; Nos C; Bonaventura I; Arroyo R; Genis D; Sureda B; Ara JR; Brieva L; Martín J; Saiz A; Sánchez López F; Prieto JM; Roquer J; Dorado JF; Montalban X
    Neurology; 2004 Aug; 63(3):525-8. PubMed ID: 15304586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS.
    Rice GP; Ebers GC; Lublin FD; Knobler RL
    Neurology; 1999 Jun; 52(9):1893-5. PubMed ID: 10371541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy.
    Reess J; Haas J; Gabriel K; Fuhlrott A; Fiola M
    Mult Scler; 2002 Feb; 8(1):15-8. PubMed ID: 11936482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Betaseron for multiple sclerosis. Implications for therapeutics.
    Rudick RA
    Arch Neurol; 1994 Feb; 51(2):125-8. PubMed ID: 8304836
    [No Abstract]   [Full Text] [Related]  

  • 6. Liver injury associated with the beta-interferons for MS.
    Francis GS; Kaplowitz N; Alteri E
    Neurology; 2004 Sep; 63(6):1142-3; author reply 1142-3. PubMed ID: 15457586
    [No Abstract]   [Full Text] [Related]  

  • 7. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS.
    Río J; Nos C; Marzo ME; Tintoré M; Montalban X
    Neurology; 1998 Jun; 50(6):1910-2. PubMed ID: 9633761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
    Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
    Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon beta but not glatiramer acetate therapy aggravates headaches in MS.
    Pöllmann W; Erasmus LP; Feneberg W; Then Bergh F; Straube A
    Neurology; 2002 Aug; 59(4):636-9. PubMed ID: 12196668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Interferon therapy of multiple sclerosis. A question of the correct dose?].
    Hohlfeld R
    Nervenarzt; 2001 Feb; 72(2):67-8. PubMed ID: 11256156
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacological treatment of early multiple sclerosis.
    Stüve O; Bennett JL; Hemmer B; Wiendl H; Racke MK; Bar-Or A; Hu W; Zivadinov R; Weber MS; Zamvil SS; Pacheco MF; Menge T; Hartung HP; Kieseier BC; Frohman EM
    Drugs; 2008; 68(1):73-83. PubMed ID: 18081373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treat early, but treat hard: Interferon-beta dose makes a difference.
    Mikol DD
    J Neuroophthalmol; 2001 Dec; 21(4):237-9. PubMed ID: 11756850
    [No Abstract]   [Full Text] [Related]  

  • 15. Interrupted therapy: stopping and switching of the beta-interferons prescribed for MS.
    Tremlett HL; Oger J
    Neurology; 2003 Aug; 61(4):551-4. PubMed ID: 12939437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].
    Federal service on surveillance in healthcare and social development (Roszdravnadzor)
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(2 Pt 2):93-8. PubMed ID: 21916163
    [No Abstract]   [Full Text] [Related]  

  • 17. Disease modifying treatment in multiple sclerosis.
    Fuller GN; Bone I
    J Neurol Neurosurg Psychiatry; 2001 Dec; 71 Suppl 2(Suppl 2):ii20-1. PubMed ID: 11701780
    [No Abstract]   [Full Text] [Related]  

  • 18. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Interferons beta in patients with multiple sclerosis].
    Vlasov IaV; Kuznetsova NI; Poverennova IE; Khivintseva EV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(7):54-5. PubMed ID: 16117149
    [No Abstract]   [Full Text] [Related]  

  • 20. Lethal capillary leak syndrome after a single administration of interferon beta-1b.
    Niederwieser G
    Neurology; 2000 Apr; 54(7):1545-6. PubMed ID: 10751284
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.